Case-control genetic association studies are often used to examine the role of the genetic basis in complex diseases, such as cancer and neurodegenerative diseases.
INTRODUCTION
Genetic association studies that estimate the relationship between gene-environment interactions (GxE) and a complex disease have the potential to provide valuable clues to the underlying aeteology of complex diseases, such as cancer and neurodegenerative disease. Case-control studies sample a set of cases and a set of healthy controls conditionally on the disease status that is often defined based on the observed clinical diagnosis. A commonly overlooked complication is that multiple pathologic mechanisms might share symptoms and hence result in the same clinical diagnosis, i.e. the set of cases might be contaminated by a subset with a nuisance pathologic diagnosis. Frequencies of the pathologic diagnosis of interest within the set of clinically diagnosed cases might vary by the environment.
Our motivating study is a GWAS of late-onset Alzheimer s disease (AD), a neurodegenerative disorder that is clinically characterized by progressive mental decline, but histopathologically defined by highly abundant amyloid deposits and neurofibrially tangles in the brain (Potter and Wisniewski, 2012) . Recent biomarker studies of AD (Salloway and Sperling, 2015; Salloway et al, 2014) reported that 36% of ApoE !4 non-carriers and 6% in ApoE !4 carriers clinically diagnosed with AD do not have evidence of amyloid deposition and hence do not qualify for the pathologic (true) diagnosis of AD.
We are interested in estimating the association between the genetic variants serving adaptive immune system and the true, pathologically confirmed, AD status. The effect of the genetic variants might vary by the ApoE !4 status and in the context of this study we define ApoE !4 to be the environment. It is possible that the symptoms resulting in the clinical diagnosis are manifestations of an underlying polygenic mechanism and hence the clinical diagnosis is a surrogate of the true diagnosis. It is also possible that the symptoms with and without the amyloid deposition evidence represent diverse mechanisms each with a distinct genetic basis. In the latter case the usual logistic model with the clinical diagnosis as an outcome is based on a misclassified disease status and hence misspecifies the link between GxE and the AD status.
Traditionally, case-control GWAS are analyzed in a logistic regression model as if the data are collected prospectively based on a justification provided by Prentice and Pyke (1979) . In the situation when the disease status is misclassified with frequencies varying by the environment, the result of Prentice and Pyke (1979) does not naturally extend.
Extensive literature (Carroll et al, 2006) reports how the estimates of the main genetic effects can be biased in situations when the disease status is misclassified. We have recently examined bias in GxE when misclassification probabilities vary by the environment and proposed a solution that alleviates the bias (Lobach et al, 2018) . This solution requires optimization of a complex non-linear function. Interestingly, Neuhaus (1999) derived a general approximation to the bias in a univariate setting when the data are collected prospectively and are analyzed in the logistic regression model. We extend the literature by deriving a general theoretical bias and a convenient approximation to the bias for GxE when the data are collected retrospectively and hence in a logistic regression model where both the design of data collection and presence of the nuisance pathologic diagnosis in the set of cases are ignored.
MATERIALS AND METHODS
We define $ be the genotype, e.g. SNPs measured at multiple locations. Let % be the environmental variable that interacts with $. We assume that the genotype is independent of all environmental variables and the genotypes follows Hardy-Weinberg Equilibrium: $~'(), +).
We define . 
In the second setting we consider the risk model is defined separately for . = 1 vs.
Suppose that the clinical-pathological diagnoses relationship is ignored and the clinical diagnosis is used as the outcome variable. Then the risk model is
Derivations provided in Online Methods show that
Remarks on formulas (6)- (9 We next suppose that the true model is (2), while the parameters are estimated based on a misspecified model (3).
Derivations provided in Appendix show that Online Methods section describes extensive simulation studies where we examined performance of the approximation empirically.
Simulation Experiments
We perform a series of simulation experiments to evaluate the accuracy of the proposed approximation. We set our other parameters to be similar to the values observed in our GWAS of AD. We let the genotype ($) be a Bernoulli random variable with frequency of 0.10 to mimic a SNP and allow its effect to follow a recessive or dominant model. We 
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Alzheimer's Disease
We applied the proposed analyses to a dataset collected as part of the Alzhemer's Disease Genetics Consortium. The data consists of 1,245 controls and 2,785 cases.
The average age (SD) of Cases and controls are 72.1 (9.1) and 70.9 (8.8) years, respectively. Among cases, 1,458 (52.4%) are men; among controls, 678 (63.9%) are men. At least one ApoE !4 allele is present in (64.5%) of cases and 365 (29.1%) of controls.
Illumina Human 660K markers have been mapped onto human chromosomes using NCBI dbSNP database (https://www.ncbi.nlm.nih.gov/projects/SNP/). Chromosome location, proximal gene or genes and gene structure location (e.g. intron, exon, intergenic, UTR) has been recorded for all SNPs. We inferred the adaptive immune system pathways based on the information from Kyoto Encyclopedia of Genes and Genomes (www.genome.jp/kegg) (KEGG), gene ontology (GO) consortium (www.geneontology.org) and Ariadne Genomics (www.ariadnegenomics.com). From these data with quality control measures (observed frequency of minor allele >5%), we inferred 133 SNPs to reside in genes serving the adaptive immune system.
It is of interest to examine a relationship between the pathologic diagnosis and each of the 133 SNPs ($), ApoE !4 status (%), age (t g ), sex (t x ). The effect of SNPs might vary by ApoE !4 hence we included interaction between the genotype and ApoE !4 status.
The genetic variables are modeled using a binary indicator of presence or absence of a minor allele.
We estimate parameters using the standard logistic model (3) that uses the clinical diagnosis as a surrogate of the pathophysiologic. We assume that the proportion of nuisance disease is as estimated by Salloway (2015) study, i.e. the proportion of the nuisance disease within the clinically diagnosed set of cases is 36% in ApoE !4 noncarriers and 6% in ApoE !4 carriers. We first assume that the true model is (1), i.e. the susceptibility model is defined for amyloid-related AD symptoms vs. healthy controls and non-amyloid AD symptoms combined. In this setting we estimate the magnitude of bias using approximation (A11.1-A15.1). We next assume that the true model is (2) Table 3 to the amyloid pathway using KEGG and GO. SNP, rs10059242, residing in an intergenic region between HTR4 and ADRB2 (ADRB2 is found to be in the amyloid pathway), has the main effect of d L â = 1.5, : = 0.04, with bias ≈ −0.9 (1), 1.8 (2) and the GxE interaction of d L×}ä = −2.0, : = 0.04 with bias ≈ −0.9 (1), −2 (2).
For three SNPs, rs401904, rs1748383, and rs12692222, the estimates in the usual logistic model (3) are nearly zero, while biases estimated assuming model (1) is true are nearly zero as well. This is consistent with the theoretical observations that the null effect estimate based on the logistic regression can be unbiased.
DISCUSSION
We derived a simple and general approximation to bias in GxE parameter estimates when multiple pathologic mechanisms present with the same set of symptoms. The approximation to the bias relies on the estimates of the frequencies of the pathologic disease state within the clinical diagnosis. The approximation that we derived complements a recent study (Lobach et al, 2018) where we developed a pseudolikelihood method to incorporate uncertainty about clinical-pathological diagnoses relationship, where the solution requires optimization of a complex non-linear function. The approximation that we derived provides a simple formula that is intuitive and easy to apply.
We observed that parameter estimates could be substantially biased when presence of the nuisance pathology is ignored. This observation has been also made by Manchia et al (2013) , where the simulation studies and data analyses on the main effect of genotype showed that the risk parameter estimates attributable to the genetics could be largely underestimated.
In our analysis of Alzheimer's disease the reliability study is based on 1,121 carriers of ApoE !4 allele and 1,331 non-carriers of ApoE !4 allele. Hence we suppose that the clinical-pathological diagnoses relationship is estimated reasonably reliably well.
Moreover, the reliability study is performed on the same patient population, i.e. patients followed-up by the Alzheimer's disease centers. There is substantial, although not exactly known, overlap between the set with genotypes and the reliability set. In general, we advocate sensitivity analyses that examine potential differences in the parameter estimates due to misspecifications of frequencies of the pathologic diagnosis within the set of clinically defined cases.
While our study is motivated by a specific example of Alzheimer's disease, the application of the approximation that we derived is readily applicable to other diseases. 
